Anti-CD19 CAR T cells have shown unparalleled response rates in haematologic malignancies, leading to the approval for treatment of acute lymphoblastic leukemia (ALL) and advanced B-cell lymphoma [2–4]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.